HYSBYSIAD O DDYFARNU CONTRACT - CENEDLAETHOL

1 Manylion yr Awdurdod

1.1

Enw a Chyfeiriad yr Awdurdod

2 Manylion y Contract

2.1

Teitl

Provision of the Oncotype DX Breast Recurrence Score Test for use within Cancer Services.

2.2

Disgrifiad o'r contract

The Oncotype DX Breast Recurrence Score Test provides a genomic-based risk assessment for early-stage invasive breast cancer in the adjuvant setting. The test provides information of distance recurrence, the benefit from chemotherapy and whether a patient can be treated effectively with hormonal therapy alone.

NICE have recommended Oncotype in the node negative setting. Local audits have suggested that use of Oncotype reduces chemotherapy use by about one third in the target population.

2.3

Cod a Dosbarthiad yr Hysbysiad

2.4

Amcangyfrif o Gyfanswm Gwerth

3 Gweithdrefn

3.1

Math o Weithdrefn

4 Dyfarnu Contract

4.1

Cynigwyr Llwyddiannus

4.1.1

Enw a Chyfeiriad y cyflenwr, contractwr neu ddarparwr gwasanaeth llwyddiannus

5 Gwybodaeth Arall

5.1

Rhif cyfeirnod a roddwyd i'r hysbysiad gan yr awdurdod contractio

SBU-DCO-017-RC-26

5.2

Dyddiad Dyfarnu'r Contract

5.3

Nifer y tendrau a dderbyniwyd

1

5.4

Gwybodaeth Arall

For continuity of service, this contract is to be renewed through a direct award under the terms and conditions of the NHS SC Laboratory Diagnostics, Point of Care Testing and Pathology Managed Service 2023/S 000-0288931, which offers a compliant route to market.

(WA Ref:168158)

5.5

Dogfennaeth Ychwanegol

5.6

Dyddiad cyhoeddi'r hysbysiad hwn: